News & Updates

Show Multimedia Only

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

The 2025 guidelines set by the American Urological Association (AUA) improve stratification of patients with microscopic hematuria (MH) into risk groups for urothelial cancer, but not renal cortical neoplasms of any kind, according to a study.

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

a day ago

Enzalutamide improves outcomes in prostate cancer with hrBCR

a day ago by

Treatment with enzalutamide monotherapy demonstrates numerically higher overall survival (OS) in prostate cancer patients with high-risk biochemical recurrence (hrBCR) when compared with leuprolide alone, but the difference is not statistically significant, as shown by the results of the EMBARK study.

Enzalutamide improves outcomes in prostate cancer with hrBCR

a day ago

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Premenopausal breast cancer patients who are receiving tamoxifen as adjuvant hormone therapy appear to be at increased risk of uterine diseases, including endometrial cancer, according to a target trial emulation study from Taiwan.

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

23 Mar 2026

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

21 Mar 2026 by

Journeying with breast cancer (BC) survivors through holistic multidisciplinary care enables them to cope better with physical and emotional stress, improves survivorship and adherence to endocrine therapy, and reduces recurrence risk, emphasized BC coach, Ms Isabel Galiano, and a multidisciplinary oncology care panel at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

21 Mar 2026

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

19 Mar 2026 by

Extended analysis of the phase III PHILA trial confirms superiority of pyrotinib in combination with trastuzumab and docetaxel (TD) vs placebo in combination with TD in sustaining longer progression-free survival (PFS) and improving overall survival (OS) in treatment-naïve patients with HER2-positive (HER2+) metastatic breast cancer (mBC).

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

19 Mar 2026

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

19 Mar 2026 by

A randomized phase II trial reports feasibility of and trends towards improved progression-free survival (PFS) and overall survival (OS) with medically supervised ketogenic diet (MSKD) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (PDAC) receiving gemcitabine, nab‐paclitaxel and cisplatin chemotherapy.

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

19 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

New drug applications approved by US FDA as of 1-15 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026 by

In the treatment of patients with muscle-invasive bladder cancer (MIBC), a perioperative regimen of the antibody–drug conjugate sacituzumab govitecan plus pembrolizumab yields a promising clinical complete response rate without eliciting grade ≥4 adverse events (AEs), allowing bladder preservation without further therapy in some patients, according to the phase II SURE-02 trial.

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026 by

In patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy, neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab elicits improvements in event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rate relative to neoadjuvant gemcitabine plus cisplatin, according to the phase III KEYNOTE-B15 study.

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

17 Mar 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

AUA 2025 guidelines help predict urothelial neoplasm risk in MH patients

Enzalutamide improves outcomes in prostate cancer with hrBCR

Enzalutamide improves outcomes in prostate cancer with hrBCR

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Tamoxifen use linked to risk of uterine diseases in premenopausal breast cancer patients

Malignant disease may re-emerge following SOT among cancer survivors

Malignant disease may re-emerge following SOT among cancer survivors

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

Phase III PHILA final analysis: Pyrotinib + trastuzumab and docetaxel prolongs PFS & OS in HER2+ Tx-naïve mBC

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

Medically supervised ketogenic diet shows trends of improved PFS & OS in pancreatic cancer patients on chemo

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Bladder-sparing regimen for MIBC shows promising antitumour activity

Bladder-sparing regimen for MIBC shows promising antitumour activity

Enfortumab vedotin plus pembrolizumab extends survival in MIBC

Enfortumab vedotin plus pembrolizumab extends survival in MIBC